“Darnitsa has won an international tender and will be able to supply medicines to 80 countries
27 March 2025 12:56
The Pharmaceutical Company “Darnitsa” has won an international tender organized by the United Nations Population Fund and received the right to supply its medicines to 80 countries in Europe, Asia and Latin America. This was reported by the company, according to
To participate in the tender, Darnitsa for the first time developed trilingual packaging for the drug in English, Spanish and French.
The company also reported that during the full-scale war, Darnitsa brought 44 new medicines to the market.
Thus, 19 new medicinal products were launched in 2022, 11 – in 2023, and 14 – in 2024.
Due to the high quality standards of production and compliance with the European GMP requirements, Darnitsa’s medicinal products are already available in more than 20 countries of the world.
What is the GMP quality standard?
This is a generally recognized global standard for pharmaceutical production. It is mandatory for the European market. In Ukraine, GMP is harmonized with the current standards of the European Union.
GMP requirements apply to all processes of pharmaceutical manufacturing – from the last stages of development to market entry. A company’s GMP certificate confirms that the products are manufactured under strictly regulated conditions that exclude the ingress of foreign substances, have the required quantitative and qualitative composition, are packaged properly, i.e. retain their properties throughout the entire shelf life, are stored and transported in appropriate conditions, and are of high quality, safe and effective.
The National Pharmaceutical Company “Darnitsa” received the updated GMP certificates on October 6, 2022. Since 2016, the company has also had a GMP certificate issued by the Lithuanian regulatory authority, and since 2022 – by the Australian regulatory authority.
The company also reminded that Darnitsa, being aware of its social responsibility, did not raise the prices for medicines during the full-scale war, and from February 25, 2025, it reduced the prices for the 20 most popular medicines by 30%.
By the way, the list of medicines for which prices have been reduced is yet to be updated with new medicines. This was reported by Petro Bahriy, President of the Association of Pharmaceutical Manufacturers of Ukraine.
What is the Ukrainian pharmaceutical market like?
In 2024, total pharmacy sales of “pharmacy basket” products reached UAH 194.7 billion, which is 19% more than in 2023. In physical terms, retail sales amounted to about 1.3 billion packs, which is 1% higher than the previous year. This is stated in the review of the pharmaceutical market by Proxima Research.
In 2024, there was an increase in the share of domestic products in monetary terms compared to 2023.
The weighted average cost of 1 package of pharmacy basket goods in 2024 amounted to UAH 150.4, which is 17.7% more than in 2023. Dietary supplements remained the most expensive category, with a weighted average cost of UAH 188.0 per pack. For medicines, this figure was UAH 182.3, for cosmetics – UAH 156.7, and for medical devices – UAH 41.6.
By the end of 2024, retail sales of medicines reached UAH 153.1 billion, which is 17.8% more than in 2023.
Who are the key market players
Three Ukrainian companies were the leaders in pharmacy sales of medicines and dietary supplements in monetary terms in 2024: “Farmak, Darnitsa and Kyiv Vitamin Plant. Nurofen, Xarelto, and Nimessil were the top brands.
In 2024, Optima-Pharm, BaDM and Venta.LTD held leading positions among distributors. Competition between key players remained high.
The pharmaceutical market is expected to grow further in 2025. According to forecasts, pharmacy sales of medicines in 2025 will increase by 16.1% in monetary terms.
